These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33212807)

  • 1. Phage Prevalence in the Human Urinary Tract-Current Knowledge and Therapeutic Implications.
    Żaczek M; Weber-Dąbrowska B; Międzybrodzki R; Górski A
    Microorganisms; 2020 Nov; 8(11):. PubMed ID: 33212807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophages of the Urinary Microbiome.
    Miller-Ensminger T; Garretto A; Brenner J; Thomas-White K; Zambom A; Wolfe AJ; Putonti C
    J Bacteriol; 2018 Apr; 200(7):. PubMed ID: 29378882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophages of the lower urinary tract.
    Garretto A; Miller-Ensminger T; Wolfe AJ; Putonti C
    Nat Rev Urol; 2019 Jul; 16(7):422-432. PubMed ID: 31073244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli.
    Valério N; Oliveira C; Jesus V; Branco T; Pereira C; Moreirinha C; Almeida A
    Virus Res; 2017 Aug; 240():8-17. PubMed ID: 28746884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections.
    de Miguel T; Rama JLR; Sieiro C; Sánchez S; Villa TG
    Antibiotics (Basel); 2020 Jul; 9(8):. PubMed ID: 32751681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Tract Infection and Microbiome.
    Kim DS; Lee JW
    Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of phage cocktails in the inactivation of Enterobacter cloacae--An in vitro study in a buffer solution and in urine samples.
    Pereira S; Pereira C; Santos L; Klumpp J; Almeida A
    Virus Res; 2016 Jan; 211():199-208. PubMed ID: 26541317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections.
    Nishikawa H; Yasuda M; Uchiyama J; Rashel M; Maeda Y; Takemura I; Sugihara S; Ujihara T; Shimizu Y; Shuin T; Matsuzaki S
    Arch Virol; 2008; 153(3):507-15. PubMed ID: 18188500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of polyvalent bacteriophages specific to uropathogenic Proteus mirabilis strains based on the host range pattern and RFLP.
    Maszewska A; Wójcik E; Ciurzyńska A; Wojtasik A; Piątkowska I; Dastych J; Różalski A
    Acta Biochim Pol; 2016; 63(2):303-10. PubMed ID: 26730411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Population-Based Surveillance Study of Shared Genotypes of Escherichia coli Isolates from Retail Meat and Suspected Cases of Urinary Tract Infections.
    Yamaji R; Friedman CR; Rubin J; Suh J; Thys E; McDermott P; Hung-Fan M; Riley LW
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30111626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused by
    Zalewska-Piątek B; Piątek R
    Antibiotics (Basel); 2020 Jun; 9(6):. PubMed ID: 32517088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing urinary tract infections through phage therapy: a novel approach.
    Malik S; Sidhu PK; Rana JS; Nehra K
    Folia Microbiol (Praha); 2020 Apr; 65(2):217-231. PubMed ID: 31494814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of
    Tan D; Zhang Y; Cheng M; Le S; Gu J; Bao J; Qin J; Guo X; Zhu T
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31752386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bacteriophages journey through the human body.
    Barr JJ
    Immunol Rev; 2017 Sep; 279(1):106-122. PubMed ID: 28856733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questions and challenges associated with studying the microbiome of the urinary tract.
    Bao Y; Al KF; Chanyi RM; Whiteside S; Dewar M; Razvi H; Reid G; Burton JP
    Ann Transl Med; 2017 Jan; 5(2):33. PubMed ID: 28217698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.
    Asadi Karam MR; Habibi M; Bouzari S
    Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivering phage therapy per os: benefits and barriers.
    Zelasko S; Gorski A; Dabrowska K
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage-bacteria interaction network in human oral microbiome.
    Wang J; Gao Y; Zhao F
    Environ Microbiol; 2016 Jul; 18(7):2143-58. PubMed ID: 26036920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.